Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curosurf in Infants with Bronchiolitis and ARDS
NCT03959384Phase 3Terminated
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
- Start
- Jan 2019
- Primary completion
- Apr 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bronchiolitis and acute respiratory distress syndrome (ARDS) comparing Curosurf with Placebo (2 arms). Primary endpoint: Number of days free from invasive mechanical ventilation at 14 days. Started Jan 2019; status: terminated.
02
Drugs
Poractant alfa
03
Conditions
bronchiolitisacute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT03959384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03959384.